Evaluating the cost-effectiveness of an early detection of Parkinson's disease through innovative technology

被引：6
|
作者：
Munoz, David A. [1 ,2 ]
Kilinc, Mehmet Serdar [1 ,2 ]
Nembhard, Harriet B. [1 ,2 ]
Tucker, Conrad [1 ,3 ]
Huang, Xuemei [4 ]
机构：
[1] Penn State Univ, Dept Ind & Mfg Engn, University Pk, PA 16802 USA
[2] Penn State Univ, Clin & Translat Sci Inst, University Pk, PA 16802 USA
[3] Penn State Univ, Dept Engn Design, University Pk, PA 16802 USA
[4] Penn State Univ, Coll Med, Hershey, PA USA
来源：
ENGINEERING ECONOMIST | 2017年 / 62卷 / 02期
基金：
美国国家卫生研究院;
关键词：
WILLINGNESS-TO-PAY; DEEP BRAIN-STIMULATION; ADJUSTED LIFE YEAR; QUALITY-OF-LIFE; EARLY-DIAGNOSIS; EFFECTIVENESS THRESHOLD; HEALTH; RECOMMENDATIONS; NICE;
D O I：
10.1080/0013791X.2017.1294718
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
Early detection of Parkinson's disease (PD) is critically important because it can increase patient quality of life and save treatment costs. An innovative approach for early detection of PD is to use nonwearable sensors that are capable of capturing skeletal joint data. This article evaluates the cost-effectiveness of this sensor-based intervention considering the quality-adjusted life years (QALYs) and the associated costs. The results indicate that the intervention would be cost-effective if devices were deployed for community health screening in public places such as health fairs and pharmacies.
引用
收藏
页码：180 / 196
页数：17
相关论文
共 50 条
  • [1] Cost-effectiveness analysis of pramipexole in early Parkinson's disease
    Noyes, K
    Dick, AW
    Holloway, RG
    VALUE IN HEALTH, 2003, 6 (03) : 274 - 274
  • [2] Cost-Effectiveness and Cost-Utility of Early Levodopa in Parkinson's Disease
    Verschuur, Constant V. M.
    Suwijn, Sven R.
    de Haan, Rob J.
    Boel, Judith A.
    Post, Bart
    Bloem, Bas R.
    van Hilten, Johannes J.
    van Laar, Teus
    Tissingh, Gerrit
    Munts, Alexander
    Dijkgraaf, Marcel G. W.
    de Bie, Rob M. A.
    JOURNAL OF PARKINSONS DISEASE, 2022, 12 (07) : 2171 - 2178
  • [3] Cost-effectiveness of neurostimulation in Parkinson's disease with early motor complications
    Dams, Judith
    Balzer-Geldsetzer, Monika
    Siebert, Uwe
    Deuschl, Guenther
    Schuepbach, W. M. Michael
    Krack, Paul
    Timmermann, Lars
    Schnitzler, Alfons
    Reese, Jens-Peter
    Dodel, Richard
    MOVEMENT DISORDERS, 2016, 31 (08) : 1183 - 1191
  • [4] Cost-effectiveness of pramipexole compared with piribedil in early Parkinson's disease patients
    Chikina, ES
    Gusev, EL
    Belousov, YB
    Guecht, AB
    VALUE IN HEALTH, 2005, 8 (03) : 321 - 321
  • [5] Pharmacotherapy in the management of early Parkinson's disease: cost-effectiveness and patient acceptability
    Cubo, Esther
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2010, 2 : 127 - 134
  • [6] COST-EFFECTIVENESS ANALYSIS OF PRAMIPEXOLE EXTENDED RELEASE MONOTHERAPY IN EARLY PARKINSON'S DISEASE
    Belousov, D.
    Afanasieva, E.
    VALUE IN HEALTH, 2015, 18 (07) : A757 - A757
  • [7] Cost effectiveness of pharmacotherapies in early Parkinson's disease
    Eggert, Karla M.
    Reese, Jens P.
    Oertel, Wolfgang H.
    Dodel, Richard
    CNS DRUGS, 2008, 22 (10) : 841 - 860
  • [8] Cost Effectiveness of Pharmacotherapies in Early Parkinson’s Disease
    Karla M. Eggert
    Jens P. Reese
    Wolfgang H. Oertel
    Richard Dodel
    CNS Drugs, 2008, 22 : 841 - 860
  • [9] Cost-effectiveness of pramipexole in Parkinson's disease in the United States
    Hoerger, TJ
    Bala, MV
    Rowland, C
    Greer, M
    Holloway, R
    NEUROLOGY, 1998, 50 (04) : A298 - A299
  • [10] Cost-effectiveness analysis of spa therapy in Parkinson's disease
    Brefel-Courbon, C
    Desboeuf, K
    Thalamas, C
    Galitzky, M
    Senard, JM
    Rascol, O
    MOVEMENT DISORDERS, 2002, 17 : S73 - S73
12345